<div id="readability-page-1"><p>Shares of AbbVie Inc. (NYSE:ABBV - Get Free Report) have been assigned a consensus recommendation of &#34;Moderate Buy&#34; from the twenty-six analysts that are  covering the stock, MarketBeat.com reports. Seven analysts have rated the stock with a hold recommendation, sixteen have given a buy recommendation and three have issued  a strong buy recommendation on  the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $210.71.</p><ul><li>3 Biopharmaceutical Stocks Bucking the Sell-Off</li></ul><p>Several research firms have commented on ABBV. Erste Group Bank raised shares of AbbVie to a &#34;strong-buy&#34; rating in a research note on Monday, March 17th. Morgan Stanley  reaffirmed a &#34;hold&#34; rating on shares of AbbVie in a research note on Friday, April 11th. UBS Group raised their price objective on shares of AbbVie from $181.00 to $190.00 and gave the stock a &#34;neutral&#34; rating in a research note on Monday, February 3rd. Wells Fargo &amp; Company boosted their price target on shares of AbbVie from $210.00 to $240.00 and gave the company an &#34;overweight&#34; rating in a report on Wednesday, March 5th. Finally, Citigroup raised their target price on AbbVie from $205.00 to $215.00 and gave the company a &#34;buy&#34; rating in a report on Monday, February 3rd.</p><p><b>Get Our Latest Stock Report on ABBV</b></p><h2>AbbVie Stock Performance</h2><ul><li>MarketBeat Week in Review – 03/24 - 03/28</li></ul><p>AbbVie stock opened at $170.01 on Tuesday. The company has a market cap of $300.74 billion, a PE ratio of 70.84, a P/E/G ratio of 1.62 and a beta of 0.55. AbbVie has a 12 month low of $153.58 and a 12 month high of $218.66. The company has a fifty day moving average price of $198.01 and a two-hundred day moving average price of $187.54. The company has a debt-to-equity ratio of 17.94, a current ratio of 0.66 and a quick ratio of 0.55. </p><p>AbbVie (NYSE:ABBV - Get Free Report) last released its quarterly earnings data on Friday, January 31st. The company reported $2.16 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $2.98 by ($0.82). AbbVie had a net margin of 7.59% and a return on equity of 296.28%. During the same period last year, the business posted $2.79 EPS.  Research analysts expect that  AbbVie will post 12.31 earnings per share for the current year. </p><h2>AbbVie Announces Dividend</h2><ul><li>AbbVie Stock Boosts Portfolios With Entry Into Weight Loss Market</li></ul><p>The firm also recently declared a quarterly dividend, which will be paid on Thursday, May 15th. Shareholders of record on Tuesday, April 15th will be given a $1.64 dividend. This represents a $6.56 annualized dividend and a yield of 3.86%. The ex-dividend date of this dividend is Tuesday, April 15th. AbbVie's dividend payout ratio (DPR) is currently 273.33%. </p><h2>Insider Transactions at AbbVie</h2><p>In related news, EVP Perry C. Siatis sold 5,778 shares of the business's stock in a transaction dated Thursday, February 20th. The stock was sold at an average price of $197.90, for a total value of $1,143,466.20. Following the completion of the sale, the executive vice president now directly owns 22,381 shares of the company's stock, valued at $4,429,199.90. The trade was a 20.52 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Timothy J. Richmond sold 29,917 shares of the business's stock in a transaction that occurred on Wednesday, February 26th. The stock was sold at an average price of $202.90, for a total value of $6,070,159.30. Following the completion of the transaction, the executive vice president now owns 44,284 shares in the company, valued at $8,985,223.60. The trade was a 40.32 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 113,471 shares of company stock worth $23,426,451 over the last ninety days. 0.25% of the stock is owned by insiders. </p><h2>Institutional Inflows and Outflows</h2><p>Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Fiduciary Advisors Inc. bought a new stake in shares of  AbbVie in the fourth quarter valued at approximately $29,000.  EnRich Financial Partners LLC lifted its holdings in shares of  AbbVie by 196.4% during the 4th quarter. EnRich Financial Partners LLC now owns 166 shares of the company's stock worth $29,000 after acquiring an additional 110 shares during the last quarter.  Promus Capital LLC purchased a new position in  AbbVie in the fourth quarter worth $30,000.  Bradley &amp; Co. Private Wealth Management LLC purchased a new stake in  AbbVie during the fourth quarter valued at about $31,000.  Finally, Prudent Man Investment Management Inc. bought a new stake in  AbbVie during the fourth quarter worth about $32,000. 70.23% of the stock is currently owned by hedge funds and other institutional investors. </p><h2>About AbbVie</h2> (Get Free Report<p>AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.</p><h2>Recommended Stories</h2><ul><li>Five stocks we like better than AbbVie</li><li>Stock Sentiment Analysis: How it Works</li><li>AST SpaceMobile: 5 Reasons to Buy This Tiny Trailblazer Stock</li><li>The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number</li><li>Why Call Option Traders Are Targeting This Dividend ETF Now</li><li>ESG Stocks, What Investors Should Know</li><li>Is Alphabet Misunderstood? Here’s Why the Bulls Are Buying</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCQlY?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="600" height="385" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCQlY"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in AbbVie Right Now?</h2><p>Before you consider AbbVie, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AbbVie wasn't on the list.</p><p>While AbbVie currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

ABBV

<p>AbbVie Inc. (NYSE:ABBV) has received a consensus recommendation of "Moderate Buy" from 26 analysts. The average 12-month price target is $210.71, with 16 analysts recommending a buy and 3 a strong buy. Recent ratings include a "strong-buy" from Erste Group Bank and a price target increase from Wells Fargo to $240. AbbVie reported $2.16 EPS last quarter, missing estimates, and declared a quarterly dividend of $1.64. Insider transactions show significant stock sales by executives.</p>

AbbVie Inc. (NYSE:ABBV) Receives Average Recommendation of "Moderate Buy" from Brokerages